MULTIPLAN CORP (MPLN)

US62548M1009 - Common Stock

0.5958  -0.03 (-5.26%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to MPLN. MPLN was compared to 40 industry peers in the Health Care Technology industry. There are concerns on the financial health of MPLN while its profitability can be described as average. MPLN has a expensive valuation and it also scores bad on growth.



Quickly go to:

6

1. Profitability

1.1 Basic Checks

In the past year MPLN has reported negative net income.
MPLN had a positive operating cash flow in the past year.
In multiple years MPLN reported negative net income over the last 5 years.
MPLN had a positive operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -1.32%, MPLN belongs to the top of the industry, outperforming 84.62% of the companies in the same industry.
The Return On Equity of MPLN (-5.36%) is better than 84.62% of its industry peers.
The Return On Invested Capital of MPLN (1.97%) is better than 89.74% of its industry peers.
MPLN had an Average Return On Invested Capital over the past 3 years of 3.20%. This is below the industry average of 5.60%.
Industry RankSector Rank
ROA -1.32%
ROE -5.36%
ROIC 1.97%
ROA(3y)-2.62%
ROA(5y)-2.8%
ROE(3y)-11%
ROE(5y)-10.57%
ROIC(3y)3.2%
ROIC(5y)N/A

1.3 Margins

Looking at the Operating Margin, with a value of 17.67%, MPLN belongs to the top of the industry, outperforming 94.87% of the companies in the same industry.
Looking at the Gross Margin, with a value of 75.51%, MPLN belongs to the top of the industry, outperforming 82.05% of the companies in the same industry.
MPLN's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 17.67%
PM (TTM) N/A
GM 75.51%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.58%
GM growth 5YN/A

More info and screens

2

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), MPLN is destroying value.
Compared to 1 year ago, MPLN has more shares outstanding
The debt/assets ratio for MPLN is higher compared to a year ago.

2.2 Solvency

MPLN has an Altman-Z score of 0.17. This is a bad value and indicates that MPLN is not financially healthy and even has some risk of bankruptcy.
MPLN has a Altman-Z score of 0.17. This is comparable to the rest of the industry: MPLN outperforms 48.72% of its industry peers.
MPLN has a debt to FCF ratio of 72.31. This is a negative value and a sign of low solvency as MPLN would need 72.31 years to pay back of all of its debts.
MPLN's Debt to FCF ratio of 72.31 is fine compared to the rest of the industry. MPLN outperforms 64.10% of its industry peers.
MPLN has a Debt/Equity ratio of 2.65. This is a high value indicating a heavy dependency on external financing.
MPLN has a worse Debt to Equity ratio (2.65) than 79.49% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.65
Debt/FCF 72.31
Altman-Z 0.17
ROIC/WACC0.31
WACC6.35%

2.3 Liquidity

MPLN has a Current Ratio of 1.16. This is a normal value and indicates that MPLN is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of MPLN (1.16) is worse than 66.67% of its industry peers.
A Quick Ratio of 1.16 indicates that MPLN should not have too much problems paying its short term obligations.
MPLN has a worse Quick ratio (1.16) than 61.54% of its industry peers.
Industry RankSector Rank
Current Ratio 1.16
Quick Ratio 1.16

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 83.33% over the past year.
The Revenue for MPLN has decreased by -10.94% in the past year. This is quite bad
MPLN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 0.84% yearly.
EPS 1Y (TTM)83.33%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q95.1%
Revenue 1Y (TTM)-10.94%
Revenue growth 3Y0.84%
Revenue growth 5YN/A
Revenue growth Q2Q1.26%

3.2 Future

Based on estimates for the next years, MPLN will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.59% on average per year.
The Revenue is expected to grow by 6.43% on average over the next years.
EPS Next Y-31.24%
EPS Next 2Y2.54%
EPS Next 3Y15.59%
EPS Next 5YN/A
Revenue Next Year5.72%
Revenue Next 2Y5.89%
Revenue Next 3Y6.43%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

MPLN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MPLN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, MPLN is valued cheaply inside the industry as 94.87% of the companies are valued more expensively.
97.44% of the companies in the same industry are more expensive than MPLN, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 6.21
EV/EBITDA 8.28

4.3 Compensation for Growth

MPLN has a very decent profitability rating, which may justify a higher PE ratio.
MPLN's earnings are expected to grow with 15.59% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.54%
EPS Next 3Y15.59%

More info and screens

0

5. Dividend

5.1 Amount

MPLN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MULTIPLAN CORP

NYSE:MPLN (5/16/2024, 2:13:04 PM)

0.5958

-0.03 (-5.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap390.70M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.32%
ROE -5.36%
ROCE
ROIC
ROICexc
ROICexgc
OM 17.67%
PM (TTM) N/A
GM 75.51%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.14
Health
Industry RankSector Rank
Debt/Equity 2.65
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 1.16
Quick Ratio 1.16
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)83.33%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-31.24%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-10.94%
Revenue growth 3Y0.84%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y